TEL-AML1 Fusion Transcripts Panel

  • Product Reviews (0)
  • Citations (3)

Research Focus

Investigations on TEL-AML1 fusion transcript, resulting from t(21;21)(p13;q22),have shown to be the most frequent molecular abnormality in precursor B acute lymphoblastic leukemia (ALL) cases, occurring in about 25% of cases.

Target Disease/Application

Acute Lymphoblastic Leukemia

Chromosomal Alteration

t(12;21)(p13;q22)

Assay ID Clinical Name Gene Symbol Gene Aliases Amplicon Length  
Hs03043640_ft TEL/AML1 BCL2L14-RUNX1 BCL2L14 RUNX1 144

Specifications

General Specifications

# of assays: 1
Technology: TaqMan® Assays - Pre-formulated assay (20x or 60x mix)
Scale: Available in multiple scales
Intended Use: Research Use Only

Kit Storage

-20° C

Documents

Product Literature

 

Citations & References (3)

  • Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

Authors
Gabert J et al.
Journal
Leukemia. 2003 Dec;17(12):2318-57.
  • Quantification of TELAML1 transcript for minimal residual disease assessment in childhood acute lymphoblastic leukaemia

Authors
SeÂverine Drunat et al.
Journal
British Journal of Haematology, 2001, 114, 281-289
  • Molecular Quantification of Response to Therapy and Remission Status in TEL-AML1-Positive Childhood ALL by Real-Time Reverse Transcription Polymerase Chain Reaction.

Authors
Karlheinz Seeger et al.
Journal
CANCER RESEARCH 61, 2517–2522, March 15, 2001.